Micronutrient Deficiencies in Inflammatory Bowel Disease_ From a to Zinc - Hwang - 2012 - Inflammatory Bowel Diseases - Wiley Online Library
Adherence Issues in IBD Sunanda Kane MD MSPH Professor of Medicine Mayo Clinic Rochester.
Antibiotics and Risk of New Onset Inflammatory Bowel Disease: A Meta-Analysis Ryan Ungaro 1, Charles Bernstein 2, Richard Gearry 3, Anders Hviid 4, Kaija-Leena.
How to Assess and Manage Strictures, Abscesses, and Phlegmons in the Complicated Crohn’s Disease Patient David A Schwartz, MD Associate Professor of Medicine.
FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.
Pro: In patients with both CMV and steroid refractory ulcerative colitis, you must treat the ulcerative colitis with biologics, but you do not need to.
Evaluating and Treating Pain in IBD Eva Szigethy MD, PHD Associate Professor of Psychiatry, University of Pittsburgh Director, Medical Coping Clinic, Children’s.
1 Stephen B. Hanauer, MD Professor of Medicine & Clinical Pharmacology Chief, Gastroenterology University of Chicago.
Immunosuppressive Medications and IBD: Now and What’s Next Stephen B. Hanauer, MD University of Chicago.
State of the Art Management of Crohn ’ s Disease Talal Al-Taweel Haya Al-Habeeb Gastroenterology Center Mubarak Al-Kabeer Hospital March 2015.
DAFTAR PUSTAKA
Pro: Perioperative anti-TNF Biologics are safe and do not increase complications associated with surgery. Miguel Regueiro, M.D. Professor of Medicine Associate.
